GlobeNewswire PharmaOriginal article
Novo’s Wegovy® (semaglutide) reduced liver fat to normal levels in 9 out of 10 adults with obesity and excess liver fat – EASD2026
Data ReadoutpositiveWegovyPositive
AI Analysis
Summary
Novo Nordisk presented data showing Wegovy (semaglutide) reduced liver fat to normal levels in 9 out of 10 adults with obesity and excess liver fat at EASD2026 conference.
Clinical Trial Data
Primary Endpoint
Met
Outcome Details
Wegovy reduced liver fat to normal levels in 9 out of 10 adults with obesity and excess liver fat
Importance:6/10
Sentiment:
0.80
semaglutideWegovyobesityNAFLDliver fatEASD2026clinical data
Related Companies
Read the original article
Published by GlobeNewswire Pharma on October 1, 2026 10:45 AM